## Andrew M Wilson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5035846/publications.pdf

Version: 2024-02-01

78 papers

2,593 citations

249298 26 h-index 232693 48 g-index

80 all docs 80 docs citations

80 times ranked 3317 citing authors

#	Article	IF	CITATIONS
1	Therapeutic thoracentesis symptoms and activity: a qualitative study. BMJ Supportive and Palliative Care, 2023, 13, e190-e196.	0.8	6
2	Interstitial lung disease and specialist palliative care access: a healthcare professionals survey. BMJ Supportive and Palliative Care, 2022, 12, e748-e751.	0.8	7
3	Use of the oral beta blocker bisoprolol to reduce the rate of exacerbation in people with chronic obstructive pulmonary disease (COPD): a randomised controlled trial (BICS). Trials, 2022, 23, 307.	0.7	2
4	Effect of high-intensity interval training in adolescents with asthma: The eXercise for Asthma with Commando Joe's® (X4ACJ) trial. Journal of Sport and Health Science, 2021, 10, 488-498.	3.3	19
5	Gaps in the Care of Familial Hypercholesterolaemia in Australia: First Report From the National Registry. Heart Lung and Circulation, 2021, 30, 372-379.	0.2	14
6	Predicting asthma-related crisis events using routine electronic healthcare data: a quantitative database analysis study. British Journal of General Practice, 2021, 71, e948-e957.	0.7	12
7	Co-trimoxazole to reduce mortality, transplant, or unplanned hospitalisation in people with moderate to very severe idiopathic pulmonary fibrosis: the EME-TIPAC RCT. Efficacy and Mechanism Evaluation, 2021, 8, 1-110.	0.9	1
8	Soluble interleukin-2 receptor in exhaled breath condensate in pulmonary sarcoidosis: a cross-sectional pilot study. Journal of Breath Research, 2021, 15, 016016.	1.5	4
9	Psychometric properties of patient reported outcome measures in idiopathic pulmonary fibrosis. Chronic Respiratory Disease, 2021, 18, 147997312110339.	1.0	13
10	Evaluating the delay prior to primary care presentation in patients with lung cancer: a cohort study. BJGP Open, 2021, 5, BJGPO.2020.0130.	0.9	4
11	The construct validity and responsiveness of the EQ-5D-5L, AQL-5D and a bespoke TTO in acute asthmatics. Quality of Life Research, 2020, 29, 619-627.	1.5	6
12	Asthma, body mass and aerobic fitness, the relationship in adolescents: The exercise for asthma with commando Joe's® (X4ACJ) trial. Journal of Sports Sciences, 2020, 38, 288-295.	1.0	7
13	Randomised controlled trial of the effect, cost and acceptability of a bronchiectasis self-management intervention. Chronic Respiratory Disease, 2020, 17, 147997312094807.	1.0	3
14	Volatile organic compounds associated with diagnosis and disease characteristics in asthma $\hat{a}\in$ A systematic review. Respiratory Medicine, 2020, 169, 105984.	1.3	25
15	Opportunities to diagnose fibrotic lung diseases in routine care: A primary care cohort study. Respirology, 2020, 25, 1274-1282.	1.3	5
16	Historical database cohort study addressing the clinical patterns prior to idiopathic pulmonary fibrosis (IPF) diagnosis in UK primary care. BMJ Open, 2020, 10, e034428.	0.8	5
17	Design and rationale of a multi-center, pragmatic, open-label randomized trial of antimicrobial therapy – the study of clinical efficacy of antimicrobial therapy strategy using pragmatic design in Idiopathic Pulmonary Fibrosis (CleanUP-IPF) clinical trial. Respiratory Research, 2020, 21, 68.	1.4	17
18	Effect of Co-trimoxazole (Trimethoprim-Sulfamethoxazole) vs Placebo on Death, Lung Transplant, or Hospital Admission in Patients With Moderate and Severe Idiopathic Pulmonary Fibrosis. JAMA - Journal of the American Medical Association, 2020, 324, 2282.	3.8	32

#	Article	IF	CITATIONS
19	Plasma vitamin C concentrations and risk of incident respiratory diseases and mortality in the European Prospective Investigation into Cancer-Norfolk population-based cohort study. European Journal of Clinical Nutrition, 2019, 73, 1492-1500.	1.3	16
20	Estimating loss in quality of life associated with asthma-related crisis events (ESQUARE): a cohort, observational study. Health and Quality of Life Outcomes, 2019, 17, 58.	1.0	4
21	Barriers to specialist palliative care in interstitial lung disease: a systematic review. BMJ Supportive and Palliative Care, 2019, 9, 130-138.	0.8	21
22	Breath biomarkers in idiopathic pulmonary fibrosis: a systematic review. Respiratory Research, 2019, 20, 7.	1.4	25
23	Low-dose oral theophylline combined with inhaled corticosteroids for people with chronic obstructive pulmonary disease and high risk of exacerbations: a RCT. Health Technology Assessment, 2019, 23, 1-146.	1.3	7
24	Asthma breathomicsâ€"promising biomarkers in need of validation. Pediatric Pulmonology, 2018, 53, 263-265.	1.0	2
25	Measuring sedentary behaviors in patients with idiopathic pulmonary fibrosis using wristâ€worn accelerometers. Clinical Respiratory Journal, 2018, 12, 746-753.	0.6	12
26	Perceptions of asthma and exercise in adolescents with and without asthma. Journal of Asthma, 2018, 55, 868-876.	0.9	37
27	At-risk registers integrated into primary care to stop asthma crises in the UK (ARRISA-UK): study protocol for a pragmatic, cluster randomised trial with nested health economic and process evaluations. Trials, 2018, 19, 466.	0.7	8
28	Effect of Theophylline as Adjunct to Inhaled Corticosteroids on Exacerbations in Patients With COPD. JAMA - Journal of the American Medical Association, 2018, 320, 1548.	3.8	67
29	Prevalence of asthma, aspirin sensitivity and allergy in chronic rhinosinusitis: data from the UK National Chronic Rhinosinusitis Epidemiology Study. Respiratory Research, 2018, 19, 129.	1.4	84
30	The Efficacy and Mechanism Evaluation of Treating Idiopathic Pulmonary fibrosis with the Addition of Co-trimoxazole (EME-TIPAC): study protocol for a randomised controlled trial. Trials, 2018, 19, 89.	0.7	19
31	Asthma Breathomics and Biomedium Consideration. Chest, 2018, 153, 1283.	0.4	0
32	The Use of Online Health Forums by Patients With Chronic Cough: Qualitative Study. Journal of Medical Internet Research, 2018, 20, e19.	2.1	31
33	Measuring activity in patients with sarcoidosis - a pilot trial of two wrist-worn accelerometer devices. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2018, 35, 62-68.	0.2	0
34	The effect of coâ€trimoxazole on serum potassium concentration: safety evaluation of a randomized controlled trial. British Journal of Clinical Pharmacology, 2017, 83, 1808-1814.	1.1	14
35	Managing fatigue in sarcoidosis – A systematic review of the evidence. Chronic Respiratory Disease, 2017, 14, 161-173.	1.0	34
36	Plasma Vascular Endothelial Growth Factor Concentration and Alveolar Nitric Oxide as Potential Predictors of Disease Progression and Mortality in Idiopathic Pulmonary Fibrosis. Journal of Clinical Medicine, 2016, 5, 80.	1.0	6

3

#	Article	IF	CITATIONS
37	The Cost Effectiveness of Maintenance Schedules Following Pulmonary Rehabilitation in Patients with Chronic Obstructive Pulmonary Disease: An Economic Evaluation Alongside a Randomised Controlled Trial. Applied Health Economics and Health Policy, 2016, 14, 105-115.	1.0	20
38	Long-term mortality of hospitalized pneumonia in the EPIC-Norfolk cohort. Epidemiology and Infection, 2016, 144, 803-809.	1.0	17
39	Inhaled corticosteroid dose-response on blood eosinophils in asthma – Authors' reply. Lancet Respiratory Medicine,the, 2016, 4, e1-e2.	5.2	1
40	Use of low-dose oral theophylline as an adjunct to inhaled corticosteroids in preventing exacerbations of chronic obstructive pulmonary disease: study protocol for a randomised controlled trial. Trials, 2015, 16, 267.	0.7	20
41	The effects of maintenance schedules following pulmonary rehabilitation in patients with chronic obstructive pulmonary disease: a randomised controlled trial. BMJ Open, 2015, 5, e005921-e005921.	0.8	43
42	Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study. Lancet Respiratory Medicine, the, 2015, 3, 849-858.	5.2	443
43	Bone mineral density and fracture risk with long-term use of inhaled corticosteroids in patients with asthma: systematic review and meta-analysis. BMJ Open, 2015, 5, e008554.	0.8	41
44	Impact of Inhaled Corticosteroids on Growth in Children with Asthma: Systematic Review and Meta-Analysis. PLoS ONE, 2015, 10, e0133428.	1.1	63
45	Treating Idiopathic Pulmonary Fibrosis with the Addition of Co-Trimoxazole: An Economic Evaluation Alongside a Randomised Controlled Trial. Pharmacoeconomics, 2014, 32, 87-99.	1.7	18
46	Outcomes in idiopathic pulmonary fibrosis: A meta-analysis from placebo controlled trials. Respiratory Medicine, 2014, 108, 376-387.	1.3	68
47	Treating idiopathic pulmonary fibrosis with the addition of co-trimoxazole: a randomised controlled trial. Thorax, 2013, 68, 155-162.	2.7	161
48	Author's response: co-trimoxazole treatment in idiopathic pulmonary fibrosis. Thorax, 2013, 68, 884-885.	2.7	7
49	The at-risk registers in severe asthma (ARRISA) study: a cluster-randomised controlled trial examining effectiveness and costs in primary care. Thorax, 2012, 67, 1052-1060.	2.7	36
50	The Role of Antihistamines in Asthma Management. Treatments in Respiratory Medicine, 2006, 5, 149-158.	1.4	21
51	Safety of Sputum Induction in Moderate-to-Severe Smoking-Related Chronic Obstructive Pulmonary Disease. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2006, 3, 89-93.	0.7	17
52	The effect of beta2-adrenoceptor haplotypes on bronchial hyper-responsiveness in patients with asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2006, 61, 254-259.	2.7	13
53	Anti-inflammatory effects of once daily low dose inhaled ciclesonide in mild to moderate asthmatic patients. Allergy: European Journal of Allergy and Clinical Immunology, 2006, 61, 537-542.	2.7	24
54	Single and short-term dosing effects of levocetirizine on adenosine monophosphate bronchoprovocation in atopic asthma. British Journal of Clinical Pharmacology, 2004, 58, 34-39.	1.1	28

#	Article	IF	CITATIONS
55	An evaluation of short-term corticosteroid response in perennial allergic rhinitis using histamine and adenosine monophosphate nasal challenge. British Journal of Clinical Pharmacology, 2003, 55, 354-359.	1.1	14
56	Effects of mediator antagonism on mannitol and adenosine monophosphate challenges. Clinical and Experimental Allergy, 2003, 33, 783-788.	1.4	53
57	Peak inspiratory flow rate is more sensitive than acoustic rhinometry or rhinomanometry in detecting corticosteroid response with nasal histamine challenge. Rhinology, 2003, 41, 16-20.	0.7	6
58	Are antihistamines useful in managing asthma?. Current Opinion in Allergy and Clinical Immunology, 2002, 2, 53-59.	1.1	19
59	A comparison of once daily fexofenadine versus the combination of montelukast plus loratadine on domiciliary nasal peak flow and symptoms in seasonal allergic rhinitis. Clinical and Experimental Allergy, 2002, 32, 126-132.	1.4	56
60	Effects of fexofenadine and desloratadine on subjective and objective measures of nasal congestion in seasonal allergic rhinitis. Clinical and Experimental Allergy, 2002, 32, 1504-1509.	1.4	61
61	A comparison of topical budesonide and oral montelukast in seasonal allergic rhinitis and asthma. Clinical and Experimental Allergy, 2001, 31, 616-624.	1.4	110
62	Dose-response for adrenal suppression with hydrofluoroalkane formulations of fluticasone propionate and beclomethasone dipropionate. British Journal of Clinical Pharmacology, 2001, 52, 93-95.	1.1	25
63	Effects of monotherapy with intraâ€nasal corticosteroid or combined oral histamine and leukotriene receptor antagonists in seasonal allergic rhinitis. Clinical and Experimental Allergy, 2001, 31, 61-68.	1.4	82
64	Effects of monotherapy with intra-nasal corticosteroid or combined oral histamine and leukotriene receptor antagonists in seasonal allergic rhinitis., 2001, 31, 61.		57
65	Effects of monotherapy with intra-nasal corticosteroid or combined oral histamine and leukotriene receptor antagonists in seasonal allergic rhinitis. Clinical and Experimental Allergy, 2001, 31, 61-8.	1.4	30
66	Evaluation of the importance of head and probe stabilisation in acoustic rhinometry. Rhinology, 2001, 39, 93-7.	0.7	5
67	Effects of leukotriene receptor antagonist therapy in patients with chronic rhinosinusitis in a real life rhinology clinic setting. Rhinology, 2001, 39, 142-6.	0.7	3
68	Antiasthmatic Effects of Mediator Blockade versus Topical Corticosteroids in Allergic Rhinitis and Asthma. American Journal of Respiratory and Critical Care Medicine, 2000, 162, 1297-1301.	2.5	82
69	24 hour and fractionated profiles of adrenocortical activity in asthmatic patients receiving inhaled and intranasal corticosteroids. Thorax, 1999, 54, 20-26.	2.7	69
70	Short-term dose-response relationships for the relative systemic effects of oral prednisolone and inhaled fluticasone in asthmatic adults. British Journal of Clinical Pharmacology, 1999, 48, 579-585.	1,1	40
71	Dose response with fluticasone propionate on adrenocortical activity and recovery of basal and stimulated responses after stopping treatment. Clinical Endocrinology, 1999, 50, 329-335.	1.2	25
72	Original Paper: Views of women and their partners on general practice care received during and after a miscarriage. European Journal of General Practice, 1999, 5, 105-109.	0.9	0

#	Article	lF	CITATION
73	Adrenocortical activity with repeated administration of one-daily inhaled fluticasone propionate and budesonide in asthmatic adults. European Journal of Clinical Pharmacology, 1998, 53, 317-320.	0.8	26
74	Effects of intranasal corticosteroids on adrenal, bone, and blood markers of systemic activity in allergic rhinitisa †a †a 1aaa Journal of Allergy and Clinical Immunology, 1998, 102, 598-604.	1.5	109
75	Effects of Low and High Doses of Inhaled Flunisolide and Triamcinolone Acetonide on Basal and Dynamic Measures of Adrenocortical Activity in Healthy Volunteers. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 922-925.	1.8	31
76	Inhaled corticosteroid therapy reduces the early morning peak in cortisol and aldosterone. Clinical Science, 1998, 95, 513-7.	1.8	0
77	Dose-response Effect for Adrenal Suppression with Repeated Twice Daily Inhaled Fluticasone Propionate and Triamcinolone Acetonide in Adult Asthmatics. American Journal of Respiratory and Critical Care Medicine, 1997, 156, 1274-1277.	2.5	45
78	Adrenal suppression with high doses of inhaled fluticasone propionate and triamcinolone acetonide in healthy volunteers. European Journal of Clinical Pharmacology, 1997, 53, 33-37.	0.8	23